US-based pathology solutions provider PathAI has introduced PathAssist Derm, an AI tool that runs on an AISight image management system (IMS) to identify and measure skin lesions.

AISight is the company’s cloud-native, intelligent enterprise workflow solution that easily integrates with major laboratory information systems (LIS) and supports various scanners.

The platform features an open AI environment, incorporating AI algorithms from PathAI and third-party partners to support multiple histopathology applications.

PathAssist Derm is PathAI’s first dermatopathology AI product offering on the AISight platform, designed to support the assessment of skin specimens.

It automates the orientation, identification, prioritisation, and measurement of skin lesions.

The research tool identifies skin lesions based on possible entities in the specimen with the potential to help expedite sample review.

PathAssist Derm automates specimen orientation, preventing manual orientation of glass slides, and provides detailed measurements of the skin lesion.

It can predict 17 different skin lesion entities, including common entities like actinic keratoses and basal cell carcinomas, and rare entities such as lichenoid keratoses or melanomas.

The tool provides dermatopathology researchers with advanced characterisation of skin specimen entities, to help advance skin cancer research, said PathAI.

PathAI co-founder and CEO Andrew Beck said: “Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone.

“These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms.

“Our goal with PathAssist Derm is to provide researchers with a scalable tool that enhances dermatopathology research through AI-enabled lesion characterisation and workflow efficiency, as part of our overall vision to improve patient outcomes with AI-powered pathology.”